The pilot program is one option to support those seeking a breakthrough in the development of a vaccine to fight the current pandemic.

“….Accelerating examination of COVID-19-related patent applications, without additional fees, will permit such innovators to bring important and possibly life-saving treatments to market more quickly.”

- Andrei Iancu, Under Secretary of Commerce for Intellectual Property and Director of the USPTO

How do I qualify for the COVID-19 Prioritized Examination Pilot Program?

You qualify if you are an applicant that falls within the small or micro entity status, and if the claim(s) of your application covers a product or process that is subject to United States Food and Drug Administration (FDA) approval for use in the prevention and/or treatment of COVID-19.

See USPTO press release for further information and please get in touch with us here if you have any questions.